Peridys

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peridys

Property Description
Active ingredient Domperidone (INN)
Form Oral tablet, Oral suspension, Orally disintegrating tablet, Suppository
Pharmacological class Dopamine antagonist, Prokinetic agent, Antiemetic
Common use Relief of nausea and vomiting, enhanced gastric emptying
Origin Synthetic organic compound

Peridys: Defining the Medicine and Its Core Active Ingredient

Peridys is the proprietary medicinal product containing the single active ingredient, Domperidone (INN). The compound is a synthetic organic compound, classified chemically as a piperidine derivative. The medication is designed as a single-ingredient product, focusing the therapeutic effect on the actions of Domperidone. The formulation is made available in several high-level dosage forms, including the standard oral tablet, the rapidly absorbed orally disintegrating tablet, liquid oral suspension or drops, and the suppository, allowing for flexible oral and rectal route of administration depending on the patient's needs, including adults and adolescents.

What Pharmacological Class Does Peridys Belong To?

Peridys is classified as a dopamine antagonist with a dual function as a prokinetic agent and an effective antiemetic. The drug functions based on its mechanism of action: selectively blocking peripheral dopamine D2 and D3 receptors. Domperidone is specifically noted for its peripherally selective action, a characteristic where it primarily targets receptors in the digestive tract and the body's vomiting control center, thereby minimizing central nervous system effects. This peripheral action is a feature differentiating it from older, less selective agents.

General Therapeutic Use and Benefits of Domperidone

This combination of prokinetic and antiemetic properties defines the general therapeutic purpose of Domperidone: assisting in the relief of the symptoms of nausea and vomiting. Its mechanism facilitates efficient gastric emptying when the natural muscle movements of the stomach and upper intestine are impaired. This action provides relief in typical scenarios of discomfort related to slow digestion. For example, Domperidone is commonly used when symptoms like feeling overly full or sick are linked to reduced movement in the upper gastrointestinal tract. This information confirms that the medication is used for improving digestive movement and controlling sickness.

What side effects are possible with Peridys?

Peridys: Possible Side Effects and Safety Information

This section details the adverse reactions and safety restrictions for Domperidone (Peridys) as classified by official regulatory authorities. These effects are organized by the body system affected and their reported frequency.


Frequency-Classified Adverse Reactions

The adverse reactions are categorized based on their official regulatory frequency: Common reactions (affecting up to 1 in 10 people) include dry mouth. Reactions classified as Uncommon (affecting up to 1 in 100 people) include neurological effects such as headache and somnolence (drowsiness), psychiatric effects like anxiety, and gastrointestinal effects like diarrhea. Effects related to the reproductive system, such as galactorrhea (unusual milk production) and breast pain, are also considered uncommon.

Serious Safety Considerations and Restrictions

The most significant documented risks involve Cardiac Disorders. Post-marketing surveillance reports list serious ventricular arrhythmias, QTc prolongation, and the risk of Sudden Cardiac Death as reactions with a Frequency Not Known status. These risks are officially noted to be increased at daily oral doses greater than 30 mg and in older adults (over 60 years).

Peridys is subject to strict contraindications in specific patient populations. It is officially restricted in patients with existing cardiac diseases (e.g., congestive heart failure), known QTc prolongation, significant electrolyte disturbances, or moderate to severe hepatic impairment. It is also contraindicated with the concurrent use of certain QT-prolonging medicinal products or potent CYP3A4 inhibitors.

Overdose and Emergency Response

A Domperidone (Peridys) overdose may present with documented Central Nervous System (CNS) manifestations, including somnolence (feeling sleepy), confusion, and extrapyramidal disorder. These uncontrolled movements can include unusual eye or tongue movements, or a twisted neck. Convulsion (seizure) is also a documented overdose presentation. Overdose also affects the Cardiovascular System, with the profile including life-threatening outcomes such as QTc prolongation, ventricular arrhythmias, Torsade de Pointes, and sudden cardiac death.

Immediate medical attention is required in the event of an overdose. Regulatory guidance explicitly states that the medicine must be stopped immediately if signs of cardiac arrhythmia (a very fast or unusual heartbeat) or uncontrolled movements occur. Management is limited to symptomatic and supportive treatment, as official regulatory information indicates that no specific antidote is known. This supportive treatment may involve Electrocardiogram (ECG) monitoring due to the risk of a prolonged QT interval.

Population-specific notes from regulatory documents show that extrapyramidal symptoms are more likely to happen in children. The risk of serious cardiovascular outcomes is noted to be higher with total daily doses greater than 30 mg and in elderly patients (over 60 years).

Therapeutic Uses of Peridys

What Peridys Treats: Main Uses and Benefits


Peridys is applied in clinical settings that involve acute or unstable symptom patterns, and is used for symptoms that interfere with daily functioning. The medicine is commonly used to help with symptoms related to physical discomfort, such as nausea and vomiting.

It is relevant in situations involving recurrent or episodic manifestations where groups of symptoms may appear suddenly or fluctuate. The medicine is applied across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden and supports patients during episodes of heightened discomfort. The medicine is generally used for managing symptoms related to systemic imbalance, including physical discomfort.

“The supportive care is generally considered relevant when symptomatic management is appropriate in contexts involving heightened systemic burden.”

Quick Fact: Supports general well-being during symptomatic phases

Regulatory References

  1. European Medicines Agency (EMA) review

Eligibility and Restrictions for Use

Peridys (Domperidone) is strictly governed by regulatory eligibility rules primarily based on cardiac risk and patient status. Use is established for adults and adolescents aged 12 years and older and weighing 35 kg or more. Efficacy is not established for children below this threshold, and the medicine is no longer licensed for use in children under 12 or those weighing less than 35 kg.

The medicine is contraindicated in several groups due to the risk of serious cardiac adverse effects, including sudden cardiac death related to QTc prolongation. Absolute contraindications include patients with moderate or severe hepatic impairment, underlying cardiac diseases (such as congestive heart failure), known prolongation of cardiac conduction intervals (QTc), or significant electrolyte disturbances.

Furthermore, Peridys must not be used where stimulation of gastric motility could be harmful (e.g., gastro-intestinal haemorrhage or perforation) or in patients with a prolactin-releasing pituitary tumour.

Pregnancy and lactation status imposes restrictions: use during pregnancy is allowed only when justified by the anticipated therapeutic benefit, and the medicine is not recommended for use by breast-feeding women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Domperidone (Peridys) is characterized by strict constraints necessary to mitigate specific risks related to cardiac function and drug metabolism. These constraints are formally documented in prescribing information and lead to several required contraindications.

Formal Contraindications

Co-administration is strictly prohibited with two primary classes of medicinal products, as explicitly stated in regulatory labels:

  • QTc-Prolonging Medicines: This includes all medicinal products known to prolong the QTc interval (e.g., specific antiarrhythmics or antipsychotics). The combination is restricted due to a pharmacodynamic interaction that heightens the risk of serious ventricular arrhythmias.
  • Potent CYP3A4 Inhibitors: All potent inhibitors of the Cytochrome P450 3A4 enzyme, such as systemic azole antifungals (e.g., ketoconazole) and certain macrolide antibiotics, are contraindicated. This pharmacokinetic interaction prevents the proper metabolism of Domperidone, leading to a clinically significant increase in its plasma concentration (AUC and Cmax). The consumption of grapefruit juice is also prohibited as it acts as a potent CYP3A4 inhibitor.

Timing and Population Notes

Substances that alter gastric acidity, including H2-receptor blockers and antacids, have been shown to decrease the oral bioavailability of Domperidone. Regulatory documents require that these agents not be taken simultaneously to avoid this reduced absorption. Additionally, the regulatory profile notes that the interaction-related risk is observed to be higher in patients older than 60 years and in those with severe renal impairment due to the potential for drug accumulation.

Mechanism of Action

The mechanism of action for Domperidone is centered on the selective antagonism of dopamine D2 and D3 receptors, inducing a dual physiological modulation of upper gut motility and the emetic reflex pathway.

Peripheral Dopamine Receptor Blockade

This domain covers the drug’s primary molecular interaction: the selective blockade of Dopamine D2 and D3 receptors located in the gastrointestinal wall and the Chemoreceptor Trigger Zone (CTZ). This mechanism initiates or suppresses signaling sequences that lead to downstream physiological effects.

Mechanistic Cascade for Modulated Gastric Motility

This cascade describes the mechanism that modulates gastrointestinal movement. D2 receptor antagonism in the gut wall relieves the natural inhibitory effect of dopamine on acetylcholine-releasing neurons. This neural disinhibition modulates processes driven by cholinergic signaling patterns, resulting in increased smooth muscle contraction and altered gastric transit.

Selective Inhibition of the Emetic Reflex Cascade

This mechanism focuses on the antiemetic action, which is achieved by blocking D2 receptors in the CTZ, a major sensory point for circulating emetic substances. This antagonism modifies the early molecular steps that shape systemic physiological outcomes, resulting in the inhibition of signaling that initiates the emetic reflex cascade.

Dosage and Administration Information

How to Use Peridys: Official Administration Guidelines

Peridys (Domperidone) is administered according to a highly structured protocol defined by standard clinical protocols, ensuring its use at the lowest effective dose for the shortest duration necessary.


Official Routes, Forms, and Dosage Schedule

Administration is possible via the oral route using the standard tablet, orally disintegrating tablet, or suspension, and via the rectal route with the suppository form.

Administration Pattern Adult/Adolescent (≥12 years & ≥35 kg) Dose Frequency & Interval
Oral Dose (Tablet/Suspension) 10 mg per dose Up to three times per day (TID)
Oral Maximum Daily Dose 30 mg per 24 hours Minimum 8-hour interval between doses
Rectal Dose (Suppository) 30 mg per dose Up to two times per day (BID)

Administration Timing and Course Duration

The oral forms are instructed to be taken before meals (15 to 30 minutes prior), a timing requirement essential because food intake can delay drug absorption.

The maximum duration of the treatment course must generally not exceed one week (7 days). This restriction defines its use as a short-course intervention.

Population-Specific and Procedural Rules

For individuals with severe renal impairment, the required dosing frequency must be reduced to once or twice daily, and the dose may require further adjustment. In all patients, if a dose is missed, it should be omitted, and the regular schedule resumed; the dose must not be doubled to compensate. Liquid forms, such as the oral suspension, require accurate measurement using a specialized device to ensure proper administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Peridys

This overview summarizes the available research and clinical studies for Domperidone (Peridys), as reported in official regulatory and scientific literature. The text focuses only on the evidence structure and documented findings without providing clinical advice, dosing information, or safety details.


Evidence for Short-Term Relief of Nausea and Vomiting

Research for this use was primarily conducted using short-term, placebo-controlled randomized controlled trials (RCTs). These studies aimed to assess patient-reported outcomes describing perceived discomfort in the main study populations: adults and adolescents (12 years of age or older) experiencing acute or episodic symptoms of nausea and vomiting.

In these research scenarios, the studies monitored outcomes related to physical discomfort, such as nausea severity scores and the number of vomiting episodes. Findings describe patterns observed in the studies, where the group receiving the study medicine reported a lower average scoring for nausea and a lower frequency of vomiting episodes compared to those taking a placebo. This research provides insight into short-term changes and contributes to the broader evidence landscape.

However, the evidence is limited for long-term outcomes, as follow-up durations were restricted to typically only one week. Furthermore, research found findings were mixed or comparable to placebo in younger children (under 12 years of age) with acute conditions; therefore, the results apply primarily to the populations studied and authorized.


Understanding the Research for Gastrointestinal Movement

Peridys was studied in research exploring the classification of prokinetic agents. Research examined populations with chronic gastrointestinal discomfort associated with delayed stomach emptying, such as gastroparesis.

The evidence base is drawn from a mixture of small-scale RCTs and older observational studies. Some trials reported measurements of a shorter time taken for the stomach to empty in the study group, a functional measure known as Gastric Emptying Time (GTT). Despite these findings, the overall evidence quality varies across studies. Regulators identified the evidence as insufficient for broad use authorization in these long-term gastrointestinal motility disorders.


Evidence Gaps and Areas of Scientific Uncertainty

For the core evidence, data is limited regarding the use of the medicine for non-acute symptoms such as chronic heartburn, persistent bloating, or general digestive discomfort (dyspepsia). For these uses, regulators concluded the evidence was insufficient.

Frequently Asked Questions (FAQ)

Common questions about Peridys (FAQ)


Q: Do you take Peridys before or after eating food?

Official regulatory information describes the administration of oral forms of Peridys as being before meals, typically 15 to 30 minutes prior. This timing is specified because taking the medication after eating may slow down the absorption of the drug into the body.


Q: How long does it usually take for Peridys to start working?

Based on studies examining how the body handles the medicine, the drug is rapidly absorbed after being taken orally by people who are fasting. This timing describes when the highest concentration of the drug is typically measured, which is a pharmacokinetic indicator of its absorption phase.


Q: Is Peridys safe to take every day for a long time?

Official regulatory documents recommend that the duration of treatment should not normally be longer than one week (7 days). The medicine is primarily intended for short-course intervention. Regulatory documents note that if use exceeds this short course, the benefit/risk ratio should be re-evaluated by a physician.


Q: Does Peridys interact with birth control pills?

While there are no specific, formal contraindications listed for hormonal contraceptives, regulatory materials mention hormonal effects such as menstrual irregularities. This potential effect may be a factor to consider when using the drug alongside hormonal medicines.


Q: How is Peridys processed and eliminated by the body?

Peridys is mainly metabolized, or processed, by an enzyme system in the liver called CYP3A4. It is then mostly eliminated from the body through the feces and urine. Since very little of the unchanged drug is passed through the kidneys, regulatory documents state that a reduced dosing frequency is required for individuals with severe renal impairment.


Q: What is the main difference between Peridys and other medicines for the same stomach issues?

Peridys is officially classified as a dopamine antagonist, a type of medicine that blocks certain chemical signals. This specific action defines its dual purpose as both a prokinetic agent (modulates movement in the digestive system) and an antiemetic (controls nausea and vomiting).


Q: Is it true that Peridys can affect heart rhythm?

Official regulatory warnings confirm that Peridys has been associated with prolongation of the QT interval, which is visible on an electrocardiogram (ECG). This potential effect is linked to a rare risk of serious heart rhythm disorders, and official warnings confirm this effect is associated with specific restrictions on the drug's use.


Q: Can Peridys be taken with common pain relievers like ibuprofen?

The official product information lists specific drug classes that are strictly prohibited, such as certain antibiotics and antifungals. While common over-the-counter pain relievers like ibuprofen are not listed as prohibited, regulatory bodies state that all concurrent medications should be discussed with a healthcare professional.


Q: Is Peridys the same as Domperidone?

The proprietary medicinal product known as Peridys contains the single active ingredient, which is known universally by its non-proprietary name, Domperidone (INN). Therefore, Peridys is the brand name for the drug Domperidone.


Q: Are there any specific foods or drinks that should be avoided while on Peridys?

Yes, official regulatory documents state that the consumption of grapefruit or grapefruit juice is prohibited. This is because grapefruit acts as a potent inhibitor of the enzyme that is necessary for the proper metabolism of Peridys in the body.


Q: What happens if a person misses a dose of Peridys?

Regulatory documents state that if a scheduled dose is missed, it is to be omitted entirely. The patient should then return to their regular schedule, and the dose must not be doubled to compensate for the one that was missed.


Q: Can elderly people safely use Peridys?

Official safety warnings note that a higher risk of serious heart rhythm disorders, including sudden cardiac death, has been observed in patients who are older than 60 years. Due to the documented risks, use in this population is subject to specific regulatory restrictions.


Q: Are there any studies about Peridys's long-term effects?

Regulatory reviews of the drug note that evidence regarding its long-term effects is limited. Most primary research studies used restricted follow-up durations, typically lasting only one week. Its safety and effectiveness for use lasting longer than six months have not been established.


Q: Why do some people use Peridys for nausea that isn't related to their stomach?

The antiemetic (anti-sickness) action of the drug is achieved by blocking receptors in the Chemoreceptor Trigger Zone (CTZ). The CTZ is a sensory point in the brain that detects circulating substances, and its blockage can help inhibit signals that cause nausea, even if the origin of the sickness is not a local stomach issue.


Q: What is the maximum duration a person is usually advised to take Peridys?

The official regulatory recommendation is that the entire course of treatment should not exceed one week (7 days). This restriction defines Peridys as an intervention for short-course use only.


Q: Are there any specific safety warnings for people with liver or kidney issues when using Peridys?

Yes, Peridys is strictly contraindicated, meaning it must not be used, in patients with moderate or severe liver impairment. For those with severe kidney impairment, regulatory guidelines state that the dosing frequency needs to be reduced.


Q: Why are there different maximum recommended doses for different populations?

The maximum daily oral dose is restricted by regulatory bodies to 30 mg per 24 hours. This restriction was implemented because a higher risk of serious cardiac adverse effects was observed in patients who were taking daily doses greater than this limit.


Q: Are there different strengths or forms (like liquid) of Peridys available?

The official product information confirms that Peridys is made available in several high-level dosage forms. These include the standard oral tablet, the liquid oral suspension, the orally disintegrating tablet, and a suppository, allowing for various routes of administration.


Q: Can men and women use Peridys for the same conditions?

The official eligibility criteria for the authorized use in adults and adolescents is based on age and weight (over 12 years and ge 35 kg). Regulatory documents do not differentiate between sexes for the core authorized conditions, such as the relief of nausea and vomiting.


Q: Are there research papers supporting the use of Peridys in children?

Regulatory reviews note that evidence supporting the effectiveness of Peridys in younger children is limited. For this reason, official authorization for its use is generally restricted to adolescents who are 12 years of age or older and weigh at least 35 kg.


Q: Can Peridys be taken at the same time as their vitamins?

Official regulatory guidance advises patients to inform their healthcare provider if they are taking any other medicines or supplements, including vitamins. This scenario, like all concurrent substances, is subject to review by a healthcare professional.


Q: Is the long-term safety profile of Peridys different from its short-term use?

Official reviews have indicated that the risk of cardiovascular events, including sudden cardiac death, increases in patients taking higher doses. Since higher doses are often associated with longer or more frequent use, this establishes a difference in the risk profile based on the administered dose and duration.


Q: Can Peridys cause dizziness or lightheadedness?

While not listed as a common side effect, official warnings note that severe dizziness and fainting are symptoms that may be associated with the drug's rare, but serious, heart rhythm disorders. The potential for dizziness or lightheadedness should be noted as a rare occurrence.


Q: Does Peridys have a sedative effect?

The official product information classifies somnolence (drowsiness) as a known, though uncommon, adverse reaction. This indicates that a feeling of sleepiness is a possible effect of the medicine.


Q: Does Peridys interact with herbal supplements like St. John's Wort?

Regulatory documents explicitly contraindicate the use of potent CYP3A4 inhibitors, which are medicines that interfere with the drug's metabolism. Herbal supplements, such as St. John's Wort, can also affect this enzyme. This necessitates review by a healthcare professional when considering simultaneous use.


Q: Can you take Peridys with other prescription drugs for high blood pressure?

Official regulatory guidance states that all prescription medications, including those for high blood pressure, must be disclosed to a healthcare professional. This is because some of these medicines could affect the drug and increase the chance of side effects.


How should Peridys be stored and disposed of?

Storage and Disposal of Peridys (Domperidone)

The official regulatory documents specify that the unopened product does not require any special storage conditions and is generally stable at room temperature. The medication has an approved shelf-life of 3 years when stored correctly.


Storage Requirements

  • Protection: The medicine must be stored in its original container to protect it from light and moisture.
  • Child Safety: All formulations must be kept out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

To prevent environmental contamination, unused or expired Peridys must not be thrown away via wastewater or household waste.

Patients are instructed to return the medication to a pharmacy or utilize a drug take-back program for disposal, ensuring compliance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Peridys found in:

A-Z Index: